摘要
目的:探讨乳腺癌激素受体表达与新辅助化疗(neoadjuvant chemotherapy,NCT)后病理完全缓解(pathologic complete response,pCR)的关系,指导筛选对化疗敏感的个体。方法:选取笔者所在医院2015年1月-2019年9月收治的102例接受NCT的激素受体阳性的乳腺癌患者作为研究对象,使用免疫组化方法检测NCT前乳腺癌患者的ER、PR表达情况,NCT结束后对手术标本采用Miller-Payne病理评价,分析激素受体的表达与pCR关系。结果:ER<50%组的乳腺癌患者pCR率为66.7%,明显高于ER≥50%组的28.7%,差异有统计学意义(χ^2=8.165,P=0.004)。ER<50%且PR<50%组患者pCR率为69.2%,明显高于其他组,差异有统计学意义(P<0.05)。PR<50%组的乳腺癌患者pCR率为36.6%,PR≥50%组乳腺癌患者pCR率为32.8%,两组比较差异无统计学意义(P>0.05)。结论:激素受体阳性型乳腺癌pCR与ER表达情况有关,与PR表达情况无关。
Objective:To explore the relationship between hormone receptor expression in breast cancer and pathologic complete response(pCR)after neoadjuvant chemotherapy(NCT),and to guide the screening of individuals sensitive to chemotherapy.Method:A total of 102 patients with hormone receptor positive breast cancer who received NCT in our hospital from January 2015 to September 2019 were selected as the research objects.Immunohistochemical method was used to detect the expression of ER and PR in breast cancer patients before NCT.After the end of NCT,Miller-Payne pathological evaluation was performed on the surgical specimens.The relationship between the expression of hormone receptor and pCR was analyzed.Result:The pCR rate of breast cancer patients in the ER<50%group was 66.7%,which was significantly higher than 28.7%in the ER≥50%group,and the difference was statistically significant(χ^2=8.165,P=0.004).The pCR rate of patients in the ER<50%and PR<50%group was 69.2%,which was significantly higher than that of other groups,and the difference was statistically significant(P<0.05).The pCR rate of breast cancer patients in the PR<50%group was 36.6%,and the pCR rate of breast cancer patients in the PR≥50%group was 32.8%,and there was no statistically significant difference between the two groups(P>0.05).Conclusion:The pCR of hormone receptor positive breast cancer is related to ER expression and not to PR expression.
作者
颜翔鹏
吕艳丽
穆为民
李毅
YAN Xiangpeng;LYU Yanli;MU Weimin;LI Yi(Beijing Shunyi District Maternal and Child Health Hospital,Beijing 101300,China;不详)
出处
《中外医学研究》
2020年第23期64-66,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
乳腺癌
激素受体
新辅助化疗
PCR
Breast cancer
Hormone receptor
Neoadjuvant chemotherapy
pCR